[
  {
    "ts": null,
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763045138,
      "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "id": 137468541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs",
    "summary": "Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe",
    "url": "https://finnhub.io/api/news?id=224c640c4c70ed50db056567e878dde6ae8a1343b3912a31442527e3c4b57322",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763035200,
      "headline": "Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs",
      "id": 137468422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe",
      "url": "https://finnhub.io/api/news?id=224c640c4c70ed50db056567e878dde6ae8a1343b3912a31442527e3c4b57322"
    }
  },
  {
    "ts": null,
    "headline": "Here Are the Top Growth Healthcare Stocks Every New Investor Should Know",
    "summary": "These top growth stocks have plenty of room left to run.",
    "url": "https://finnhub.io/api/news?id=ea8176196533f6ec04b0b7df1ff8d7a877b93475688f7f72bc7061c25a773440",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763028900,
      "headline": "Here Are the Top Growth Healthcare Stocks Every New Investor Should Know",
      "id": 137466724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "These top growth stocks have plenty of room left to run.",
      "url": "https://finnhub.io/api/news?id=ea8176196533f6ec04b0b7df1ff8d7a877b93475688f7f72bc7061c25a773440"
    }
  }
]